Citi opened a “90-day positive catalyst watch” on shares of Summit Therapeutics while keeping a Buy rating on the name with a $13 price target. The company is a approaching a “critical catalyst” of detailed results from the Phase 3 HARMONi-2 trial run by Summit’s partner Akeso in China. The firm believes the data should provide confidence that ivonescimab “could emerge as a potential game-changer” in non-small cell lung cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Expands HQ and Appoints Tech Veteran
- Largest borrow rate increases among liquid names
- Summit Therapeutics Announces Board Changes and Shareholder Approvals
- Summit Therapeutics Announces Breakthrough in Lung Cancer Treatment
- Summit Therapeutics’ Strategic Expansion and $200M Financing Deal